Business Description
Thalia Therapeutics PLC
ISIN : GB00BYW8QM32
Total Employee Number:
4Description
Thalia Therapeutics PLC is a specialist pharmaceutical company engaged in the development of mesoparticulate silica delivery systems to improve the cellular delivery and potency of vaccines. The company engaged in the development of a Liptide platform to deliver a proprietary siRNA sequence to silence a fibrotic gene. The Group operated in one business segment, that of the development and commercialisation of medicines via its delivery system called Nuvec and its liptide platform called ECP105.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.92 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 32.03 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 30.7 | |||||
3-Year EPS without NRI Growth Rate | 30.7 | |||||
3-Year FCF Growth Rate | 20.6 | |||||
3-Year Book Growth Rate | -51.9 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 51.7 | |||||
9-Day RSI | 52.56 | |||||
14-Day RSI | 53.01 | |||||
6-1 Month Momentum % | -50 | |||||
12-1 Month Momentum % | -50 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 11.92 | |||||
Quick Ratio | 11.92 | |||||
Cash Ratio | 11.01 | |||||
Days Sales Outstanding | 4265.94 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -52.7 | |||||
Shareholder Yield % | -22.28 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -15325 | |||||
Net Margin % | -15062.5 | |||||
EBITDA Margin % | -15325 | |||||
FCF Margin % | -13420 | |||||
OCF Margin % | -13420 | |||||
ROE % | -103.73 | |||||
ROA % | -95.38 | |||||
ROIC % | -1318.28 | |||||
3-Year ROIIC % | 143.82 | |||||
ROC (Joel Greenblatt) % | -5180.28 | |||||
ROCE % | -105.39 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 6.5 | |||||
EV-to-EBIT | -5.53 | |||||
EV-to-EBITDA | -5.53 | |||||
EV-to-Revenue | 846.75 | |||||
EV-to-FCF | -5.83 | |||||
Earnings Yield (Greenblatt) % | -18.08 | |||||
FCF Yield % | -14.78 | |||||
Forward Rate of Return (Yacktman) % | -886.12 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Thalia Therapeutics PLC Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.01 | ||
| EPS (TTM) (€) | -0.002 | ||
| Beta | 2.4484 | ||
| 3-Year Sharpe Ratio | 0.47 | ||
| 3-Year Sortino Ratio | 4.17 | ||
| Volatility % | 905.91 | ||
| 14-Day RSI | 53.01 | ||
| 14-Day ATR (€) | 0.001515 | ||
| 20-Day SMA (€) | 0.0045 | ||
| 12-1 Month Momentum % | -50 | ||
| 52-Week Range (€) | 0.0005 - 0.0265 | ||
| Shares Outstanding (Mil) | 1,208.11 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Thalia Therapeutics PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Thalia Therapeutics PLC Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Second quarter earnings conference call for 2026 | 2026-09-25 13:00 | In 80 days | ||
| Second quarter earnings results for 2026 | 2026-09-25 | In 79 days | ||
| General meeting for 2026 | 2026-07-17 10:00 | In 10 days | ||
| Annual report for 2025 | 2026-06-24 | 0.01 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-06-23 | 0.01 (+0.00%) | ||
| Second quarter earnings conference call for 2025 | 2025-09-25 13:00 | 0.00 (+0.00%) | ||
| Second quarter earnings results for 2025 | 2025-09-25 | 0.00 (+0.00%) | ||
| General meeting for 2024 | 2025-06-30 11:00 | 0.00 (+0.00%) | ||
| Annual report for 2024 | 2025-06-06 | 0.00 (+0.00%) | ||
| Fourth quarter earnings results for 2024 | 2025-06-06 | 0.00 (+0.00%) |
Show
Entries
Thalia Therapeutics PLC Frequently Asked Questions
What is Thalia Therapeutics PLC(FRA:0GO)'s stock price today?
The current price of FRA:0GO is €0.01. The 52 week high of FRA:0GO is €0.03 and 52 week low is €0.00.
When is next earnings date of Thalia Therapeutics PLC(FRA:0GO)?
The next earnings date of Thalia Therapeutics PLC(FRA:0GO) is 2026-09-25 Est..
Does Thalia Therapeutics PLC(FRA:0GO) pay dividends? If so, how much?
Thalia Therapeutics PLC(FRA:0GO) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Thalia Therapeutics PLC
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers